Article Text

other Versions

PDF
Orbital recurrence of retinoblastoma following enucleation
  1. Jonathan Wano Kim (jwkim0103{at}yahoo.com),
  2. Vinnie Kathpalia (vinniekathpalia{at}gmail.com),
  3. Ira dunkel (dunkeli{at}mskcc.org),
  4. Ryan K Wong (rwk2001{at}med.cornell.edu),
  5. Elyn Riedel (riedele{at}mskcc.org),
  6. David H Abramson (abramsod{at}mskcc.org)
  1. Memorial Sloan-Kettering Cancer Center, United States
  2. Memorial Sloan-Kettering Cancer Center, United States
  3. Memorial Sloan-Kettering Cancer Center, United States
  4. Memorial Sloan-Kettering Cancer Center, United States
  5. Memorial Sloan-Kettering Cancer Center, United States
  6. Memorial Sloan-Kettering Cancer Center, United States

    Abstract

    Background/Aims: To determine the incidence, clinical presentation and histopathologic profile of patients developing orbital recurrence following enucleation for intraocular retinoblastoma.

    Methods: A cohort of 1674 consecutive patients undergoing enucleations between 1914-2006 was retrospectively reviewed to identify cases of orbital recurrence. A detailed chart review of all identified patients with orbital recurrence following enucleation was performed. Main outcome measures were histopathologic features of the enucleated globe, clinical presentation, status of metastatic disease, and clinical outcomes of treatment at last follow-up.

    Results: There were 71 cases of orbital recurrence identified in the study, for an incidence of 4.2% (71 of 1674 cases). The diagnosis of orbital recurrence was made between 1-24 months after enucleation (mean, 6 months), with 69 of the 71 patients being diagnosed within the first 12 months. Over a follow-up period of 3-208 months (mean, 34.8 months), 60 of 71 patients developed metastatic disease (85%), and 53 of 71 patients died from metastatic retinoblastoma (75%). For the subgroup of cases diagnosed with orbital recurrences after 1984, 10 of 11 patients are alive and well.

    Conclusions: All patients undergoing enucleation for intraocular retinoblastoma need to be followed carefully for the first two years after enucleation for the possibility of orbital relapse. The majority of retinoblastoma patients with orbital tumor recurrence develop metastatic disease, although mortality rates appear to be improving in the modern era.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.